Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
TScan Therapeutics, Inc. (TCRX) had Free Cash Flow of $-73.66M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$3.08M |
|
$-36.95M |
|
-- |
|
$3.08M |
|
$41.73M |
|
$-38.65M |
|
$1.70M |
|
$-36.95M |
|
$-36.95M |
|
$-36.95M |
|
$-36.95M |
|
$-36.95M |
|
$-36.95M |
|
$-38.65M |
|
$-37.95M |
|
129.73M |
|
129.73M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$221.13M |
|
$9.52M |
|
$77.43M |
|
$298.56M |
|
$31.32M |
|
$32.30M |
|
$90.53M |
|
$121.85M |
|
$176.71M |
|
$176.71M |
|
$176.71M |
|
56.75M |
|
| Cash Flow Statement Financials | |
$-70.85M |
|
$61.97M |
|
$-0.41M |
|
$183.72M |
|
$174.43M |
|
$-9.29M |
|
$6.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.06 |
|
-- |
|
-- |
|
0.15 |
|
0.18 |
|
100.00% |
|
-1256.60% |
|
-1256.60% |
|
-- |
|
-1201.30% |
|
-1201.30% |
|
|
Free Cash Flow |
$-73.66M |
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-20.91% |
|
-20.91% |
|
-12.38% |
|
-17.68% |
|
$3.11 |
|
$-0.57 |
|
$-0.55 |
|